A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers - Trial NCT05275465
Access comprehensive clinical trial information for NCT05275465 through Pure Global AI's free database. This Phase 1 trial is sponsored by Huahui Health and is currently Recruiting. The study focuses on Hepatitis B. Target enrollment is 33 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Huahui Health
Timeline & Enrollment
Phase 1
Apr 11, 2022
Jan 30, 2023
Primary Outcome
Number of participants with treatment emergent adverse events (TEAEs),Severity of treatment emergent adverse events as measured by CTCAE v 5.0,Duration of treatment emergent adverse events
Summary
Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to
 evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing monoclonal
 antibody in healthy volunteers, and to determine its pharmacokinetic profile and
 immunogenicity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05275465
Non-Device Trial